Summary & Overview
HCPCS Level II C9471: Hymovis (hyaluronan) intra-articular injection, 1 mg
HCPCS Level II code C9471 represents a unit of hyaluronan derivative (Hymovis) for intra-articular injection, measured per 1 mg. This code is used to bill for viscosupplementation products administered directly into a joint space, most commonly for symptomatic management of osteoarthritis. Nationally, accurate coding for intra-articular hyaluronan products affects clinical billing, payer coverage decisions, and access to treatment in outpatient orthopedic and procedural settings.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for viscosupplementation, payer coverage considerations, and the types of benchmarks and policy updates typically relevant to HCPCS Level II drug and supply codes. The publication outlines expected service settings, common billing practices tied to single-dose unit coding, and where to look for payer-specific coverage rules.
The report provides national-level benchmarks and policy summaries, highlights typical procedural settings for administration, and identifies areas where payers frequently publish utilization and prior authorization guidance. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9471 describes hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg. The service type is intra-articular hyaluronan injection intended for joint viscosupplementation. The typical site of service for this product is outpatient ambulatory settings, including orthopedic clinics and outpatient infusion or procedure rooms where intra-articular injections are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a middle-aged to older adult presenting to an orthopedics or sports medicine clinic with focal joint pain, stiffness, and functional limitation attributed to osteoarthritis of the knee. After conservative measures (oral analgesics, activity modification, physical therapy, and at least one course of intra-articular corticosteroid if appropriate) fail to provide sustained relief, the clinician discusses viscosupplementation. The procedure involves a single or series of intra-articular injections of hyaluronan derivative C9471 (Hymovis, 1 mg per unit billed) delivered in an outpatient clinic, ambulatory surgical center, or office procedure room.
The clinical workflow includes patient assessment (history, focused musculoskeletal exam), review of imaging (plain radiographs to confirm osteoarthritic changes), informed consent, skin preparation and antisepsis, optional local anesthetic, and fluoroscopic or landmark-guided intra-articular injection of the hyaluronan product. Post-procedure observation for immediate adverse effects (allergic reaction, vasovagal response, acute infection) follows, with instructions for activity modification and follow-up. Documentation includes the product name/HCPCS C9471, units administered, laterality, procedure note, and relevant diagnosis code(s). Typical sites of service are outpatient office, ambulatory surgical center, or hospital outpatient department.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|